Long-Term Follow-Up and Survival Data in Progressing Advanced Midgut Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy
#1126
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective treatment option for advanced Neuroendocrine Tumours (NET), however long term survival data is lacking.
Aim(s): To determine, whether there is a difference in long-term survival in patients exhibiting partial response or stable disease, post-PRRT, and to identify prognostic factors for overall (OS) and progression-free survival (PFS).
Materials and methods: Retrospective analysis of OS and PFS (based on radiological RECIST criteria) among a cohort of 133 patients with progressing (despite previous treatments) advanced midgut NET (who received Y-90 or Lu-177 DOTATATE). Univariate Kaplan-Meier techniques and multivariate Cox regression models were used.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Yalchin M, Oliveira A, Pencharz D, Navalkissoor S, Quigley A,
To read the full abstract, please log into your ENETS Member account.